Streetbeat News

Equity Actions

EXR

Extra Space Storage (NYSE:EXR) has been evaluated by 7 financial analysts, with a mix of opinions ranging from bullish to indifferent. The average 12-month price target for EXR is $159.71, up 9.52% from the previous target of $145.83. Analysts from firms like Deutsche Bank, Goldman Sachs, Truist Securities, Morgan Stanley, Wells Fargo, and Stifel have adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance. Extra Space Storage is a REIT with a strong market presence, significant revenue growth, high net margin, and effective asset utilization, but with a lower ROE than industry benchmarks.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 4:00 pm

AMD

An in-depth analysis compares Advanced Micro Devices (AMD) to its competitors in the Semiconductors & Semiconductor Equipment industry. AMD's P/E ratio is significantly higher than the industry average, suggesting an overvalued stock. Its P/B ratio is below the industry average, indicating potential undervaluation by book value. The P/S ratio is also higher than the industry average, hinting at overvaluation by sales. AMD's ROE is below the industry average, suggesting inefficiency in profit generation from equity. The company's EBITDA and gross profit are below the industry average, indicating potential profitability challenges. AMD's revenue growth is lower than the industry average, pointing to a slower sales performance. AMD's lower debt-to-equity ratio compared to its top 4 peers suggests a stronger financial position with less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 4:00 pm

DTC

Solo Brands (NYSE:DTC) has seen a 9.12% increase in short interest since its last report, with 4.27 million shares sold short, representing 47.4% of its float. It would take about 1.9 days to cover all short positions. High short interest can indicate bearish market sentiment but doesn't necessarily predict a price drop. Solo Brands has a higher short interest than its peer group average of 7.22%.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:30 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) received diverse analyst ratings over the last three months, with 16 analysts offering evaluations. The average 12-month price target is $74.75, with a high of $106.00 and a low of $42.00, marking a 5.28% increase from the previous average of $71.00. Analysts from firms like Oppenheimer, Needham, and Goldman Sachs have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on the complement system. It has shown a revenue growth rate of 400.54% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -127.03%, ROE of -48.55%, and ROA of -16.18%.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:01 pm

HLIT

Analysts have provided diverse opinions on Harmonic (NASDAQ:HLIT) with 5 bullish ratings in the past quarter. The average 12-month price target is $18.4, up from the previous $16.33. Analyst actions include maintaining and adjusting price targets, reflecting market conditions and company performance. Harmonic's financials show a revenue decline of -18.32% and below-average profitability metrics. The company's market cap is below industry benchmarks, and it has a conservative debt-to-equity ratio of 0.46.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

WELL

Eight analysts have recently rated Welltower (NYSE:WELL), with a mix of bullish to bearish sentiments. The average 12-month price target is $98.62, up 8.21% from the previous $91.14. Analysts from firms like Deutsche Bank, Keybanc, and JP Morgan have raised their price targets, reflecting a positive outlook on Welltower's performance. The company has shown strong revenue growth and efficient asset management but faces challenges in profitability and equity capital usage. Welltower's diversified healthcare portfolio and conservative financial approach with a low debt-to-equity ratio are also highlighted.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

RL

Eight financial analysts have recently updated their ratings for Ralph Lauren (NYSE:RL), with a mix of bullish and indifferent stances. The average 12-month price target has been raised to $144.25, up 8.3% from the previous $133.20. Analysts from firms like Raymond James, Wells Fargo, Goldman Sachs, TD Cowen, UBS, Telsey Advisory Group, and Evercore ISI Group have raised their price targets, indicating a positive outlook on the company's performance. Ralph Lauren's financials show a positive revenue trend, a high net margin, and strong ROE and ROA, with a prudent debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares dropped over 2% on Tuesday after a 65.3% decline on Monday. The company announced an abstract for SBP-101 was accepted for a poster presentation at the American Association for Cancer Research. Panbela is collaborating with Johns Hopkins University School of Medicine on this. Additionally, Panbela disclosed the pricing of a public offering of 4.38 million shares or pre-funded warrants, with two classes of warrants to purchase up to 8.75 million shares. The common warrants have an exercise price of $2.06 per share and are exercisable immediately, expiring in five years. The offering aims to raise approximately $9.0 million and is expected to close by January 31, 2024. Last week, Panbela was in news for enrolling in the ASPIRE global clinical trial for metastatic pancreatic cancer treatment.

Portfolio Pulse from Nabaparna Bhattacharya

January 30, 2024 | 2:56 pm

AAPL

AMZN

AVGO

BRK

GOOGL

LLY

META

MSFT

NVDA

SPY

JPMorgan Chase & Co.'s analysis reveals a market concentration in the top 10 stocks of the MSCI USA Index similar to the dot-com bubble peak. The 'Magnificent Seven' tech giants contribute to a 29.3% share in December, nearing the 33.2% peak of June 2000. The SPDR S&P 500 ETF Trust's top 10 holdings, dominated by tech, account for 31.8% of the index. The Nasdaq 100 to S&P 500 ratio is at an all-time high, indicating tech dominance. JPMorgan warns of risks from this concentration, suggesting a potential market correction.

Portfolio Pulse from Piero Cingari

January 30, 2024 | 2:45 pm

PALI

Palisade Bio, Inc. has announced the exercise of previously issued warrants, resulting in $2.5 million in funding for the company. This exercise of warrants is a positive development for Palisade Bio as it provides additional capital that can be used for operational expenses, research and development, or other corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 2:29 pm